Remedy Pharmaceuticals, Inc. Announces Appointment Of Chief Financial Officer

NEW YORK--(BUSINESS WIRE)--Remedy Pharmaceuticals, a clinical stage pharmaceutical company focused on the development and commercialization of a revolutionary, breakthrough drug, CIRARA™, for treating acute central nervous system conditions — where there are inadequate or no approved existing therapies — announced today the appointment of Richard I. Steinhart as Chief Financial Officer effective immediately.

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.